Table 5.
Results of the cost-utility analysis
| Chemotherapy | Antiemetic therapy | Mean cost (€) | Incremental cost (€) | Mean QALDs | Incremental QALDs | Incremental cost-utility ratio (€/QALD) |
| HEC | APR + PALO | 132.5 | – | 2.684 | – | NEPA is dominant |
| NEPA | 102.4 | −30.2 | 2.945 | +0.261 | ||
| APR + ONDA | 148.8 | – | 3.020 | – | NEPA is dominant | |
| NEPA | 100.4 | −48.4 | 3.097 | +0.077 | ||
| fAPR + PALO | 155.3 | – | 2.684 | – | NEPA is dominant | |
| NEPA | 102.4 | –52.9 | 2.945 | +0.261 | ||
| fAPR + ONDA | 171.7 | – | 3.020 | – | NEPA is dominant | |
| NEPA | 100.4 | −71.4 | 3.097 | +0.077 | ||
| MEC | APR + PALO | 125.1 | – | 2.992 | – | NEPA is dominant |
| NEPA | 97.9 | −27.2 | 3.044 | +0.052 | ||
| fAPR + PALO | 145.9 | – | 2.992 | – | NEPA is dominant | |
| NEPA | 97.9 | −48.0 | 3.044 | +0.052 |
APR, aprepitant; fAPR, fosaprepitant; HEC, highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy; ONDA, ondansetron; PALO, palonosetron; QALD, quality adjusted life day.